louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00137410: Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee
Official title: Protocol For A Multicentre, Double Blind, Parallel Group Pilot Study To Compare Celecoxib Long Term Vs Celecoxib Short Term Therapy In Treatment And Prevention Of New Flare In Patients With Osteoarthritis Of The Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Osteoarthritis,Knee
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2005-08-29
Enrollment: 200
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.


Eligibility criteria: Inclusion Criteria:

* diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
* patients in flare

Exclusion Criteria:

* any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
* clinical or radiological evidence of chondrocalcinosis

Primary outcomes:
measure: Time elapsing between the last drug administration and a new flare, if any, occurring within a 12 months FU and proportion pts with a new flare
Secondary outcomes:
measure: Flare intensity WOMAC OA index Psycho-affective Index Pt's assessment of OA pain (VAS) Pt's & Physician's global assessment disease severity Incidence of total AEs Incidence of GI AEs: Incidence of changes in: hematology, renal function, liver function
Other outcomes:
Locations:
city: Rutigliano
country: Italy
facility: Pfizer Investigational Site
state: BA
city: Arenzano (GE)
country: Italy
facility: Pfizer Investigational Site
city: Cagliari - Monserrato
country: Italy
facility: Pfizer Investigational Site
city: Foggia
country: Italy
facility: Pfizer Investigational Site
city: Genova
country: Italy
facility: Pfizer Investigational Site
city: Genova
country: Italy
facility: Pfizer Investigational Site
city: Jesi ( AN)
country: Italy
facility: Pfizer Investigational Site
city: Milano
country: Italy
facility: Pfizer Investigational Site
city: Milano
country: Italy
facility: Pfizer Investigational Site
city: Padova
country: Italy
facility: Pfizer Investigational Site
city: Palermo
country: Italy
facility: Pfizer Investigational Site
city: Pavia
country: Italy
facility: Pfizer Investigational Site
city: Potenza
country: Italy
facility: Pfizer Investigational Site
city: Roma
country: Italy
facility: Pfizer Investigational Site
city: Siena
country: Italy
facility: Pfizer Investigational Site
city: Venezia
country: Italy
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02155010: Dexmedetomidine in Spinal Anesthesia
Official title: Hemodynamic Effect of Dexmedetomidine on Heavy Bupivacaine Spinal Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Pressure
Anxiety
Keywords: Dexmedetomidine
Spinal anesthesia
Lead sponsor: Inje University
Sponsor class: OTHER
First posted: 2014-06-04
Enrollment: 74
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Patients were randomized into two groups, A group and B group. A group and B group patients are injected intravenous dexmedetomidine after intrathecal injection (IT) of heavy bupivacaine and injected intravenous dexmedetomidine before IT of heavy bupivacaine, respectively.

The investigators will compare of hemodynamics and patient's comfortability between two groups.

Detailed description: A and B group patients will intravenous inject dexmedetomidine 1mcg/kg for 10 minute loading infusion and 0.2mcg/kg/hr for continuous infusion. A group receive intravenous dexmedetomidine after procedure, and B group receive intravenous dexmedetomidine before procedure. Both group patients will hydrate 6 ml/kg crystalloid solution and will evaluated patient's anxiety and comfortability perioperative period. Vital signs will record 5 minutes interval at operating room and post-anesthetic care units.

Eligibility criteria: Inclusion Criteria:

* 20 - 60 aged patients
* orthopedic operation undergoing spinal anesthesia

Exclusion Criteria:

* more than American society of anesthesiologists classification 3
* hypertension
* diabetes mellitus
* heart disease (bradycardia, atrioventricular block)

Primary outcomes:
measure: Incidence of Hypotension
timeFrame: up to 3 hours
Secondary outcomes:
measure: Patient's Anxiety
timeFrame: up to 3 days
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Inje University, Haeundae paik hospital
Study officials:
affiliation: Inje University Haeundae Paik Hospital
name: Ki Hwa Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kang E, Lee KH, Jeon SY, Lee KW, Ko MJ, Kim H, Kim YH, Jung JW. The timing of administration of intravenous dexmedetomidine during lower limb surgery: a randomized controlled trial. BMC Anesthesiol. 2016 Nov 21;16(1):116. doi: 10.1186/s12871-016-0282-2.
Clinical trial NCT03268681: BIOtinidase Test In Optic-Neuropathy
Official title: BIOtinidase Test In Optic-Neuropathy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Biotin Deficiency
Optic Neuropathy
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2017-08-31
Enrollment: 12
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with idiopatic bilateral optic neuropathy

Brief summary: Biotinidase is an enzyme that recycles biotin, a water-soluble vitamin essential as a coenzyme for four carboxylases that are involved in gluconeogenesis, fatty acid synthesis, and in the catabolism of several branch-chain amino acids. Biotinidase deficiency (BD) is an autosomal recessively inherited disorder. Patients with profound BD (\<10% of mean normal serum biotinidase activity) presents, usually during early childhood, with neurological (seizures, hypotonia, ataxia, developmental delay, vision problems, and/or hearing loss) and non-neurological findings (metabolic acidosis, respiratory difficulties, alopecia and/or skin rash) that may progress to coma or death if untreated.

Three cases of adult-onset biotinidase deficiency with reversible optic neuropathy have recently been described in France, where there is no neonatal screening of BP. Once treated with Biotin, patients' vision was fully restored.

This study aims to assess the prevalence of BP among a population of patients with idiopathic optic neuropathy, and to assess the efficacy of Biotin supplementation on visual impairment in these patients.


Eligibility criteria: Inclusion Criteria:

* patient with bilateral optic neuropathy
* symptoms beginning before 50 years old
* diagnosed for more than 1 months
* etiology unknown

Exclusion Criteria:

* none

Primary outcomes:
measure: prevalence of biotin deficiency among patients with idiopathic optic neuropathy
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation OPH A. de Rothschild
Study officials:
affiliation: Fondation OPH A de Rothschild
name: Romain Deschamps, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03884881: Second-generation Sequencing Guides the Treatment of Severe Pneumonia
Official title: The Role of Second-generation Sequencing in the Treatment of Severe Pneumonia With Initial Treatment Failure
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pneumonia
Metagenomic Next Generation Sequencing
Lead sponsor: Xiangya Hospital of Central South University
Sponsor class: OTHER
First posted: 2019-03-21
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigators plan to conduct the participants level, 1:1 randomized trial at the Central ICU and respiratory ICU of Xiangya Hospital in Changsha, China, from January 1, 2018 to December 31, 2019. Participants with initial diagnosis of severe pneumonia will be first treated with empiric therapy, after 48-72 hours, the participants's condition will be evaluated, and participants who will have been initially cured and died should be excluded.The participants who will have failed the initial treatment will be then randomly divided into two groups: the NGS group and the conventional treatment group. Bronchoalveolar lavage fluid will be taken by bedside bronchoscopy when the participants underwent nasal high-flow oxygen therapy, non-invasive ventilation, and invasive ventilation,or venous blood will be taken for examination. Participants in the NGS group will be tested for both NGS and conventional pathogens, however, the routine group will be only routinely tested. According to the pathogen results, participants with non-severe pneumonia will be excluded, and medication should be adjusted under the joint guidance of infectious and respiratory specialists. Then investigators will compare the first outcome: 28-day mortality, and secondary outcome: ICU hospitalization time, mechanical ventilation time, Hospitalization costs, antibiotic use costs, SOFA scores, CURB-65 scores, APACHE scores, and other clinical indicators.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with severe pneumonia between the ages of 18 and 85 years; the diagnosis of severe pneumonia is based on IDSA / ATS

Exclusion Criteria:

* \< 18 years old, received antibiotic treatment within 14 days before admission, suffering from severe immunosuppression, multi-drug resistance, refractory tuberculosis, end-stage renal disease or liver disease (uremia, advanced liver cancer), pregnancy. Besides, we need to rule out patients who have been improved, died, and abandoned during the initial treatment。

Primary outcomes:
measure: mortality
timeFrame: 28 day
Secondary outcomes:
measure: mechanical ventilation time
timeFrame: 30 days
Other outcomes:
Locations:
city: Changsha
country: China
facility: Xiangya Hospital
state: Hunan
Study officials:
References:
Clinical trial NCT01797081: BOTOX® in the Treatment of Crow's Feet Lines in Japan
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Lateral Canthus Rhytides
Crow's Feet Lines
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2013-02-22
Enrollment: 300
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).


Eligibility criteria: Inclusion Criteria:

-Moderate to severe Crow's Feet Lines

Exclusion Criteria:

* Current or previous botulinum toxin treatment of any serotype
* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
* Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial peels, or topical retinoid therapy or hormone cream within 3 months
* Laser treatment or phototherapy of the face for medical purposes, blepharoplasty, brow-lift or related procedure, periorbital permanent make-up, or oral retinoid therapy within one year
* Medium-depth or deep facial peels within 5 years
* Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift, periorbital treatment with fillers, implantation or transplantation)

Primary outcomes:
measure: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)
timeFrame: Day 30
Secondary outcomes:
measure: Percentage of Participants Achieving a ≥1-Grade Improvement From Baseline on the Investigator's Assessment of the Severity of CFL at Rest Using the FWS-A
timeFrame: Day 30
measure: Percentage of Participants Much Improved or Very Much Improved in the Subject's Assessment of Appearance of CFL as Measured by the Global Assessment of Change in Crow's Feet Lines
timeFrame: Day 30
measure: Percentage of Participants Who Rate Themselves in a Younger Self-Perception of Age Category Than at Baseline
timeFrame: Day 30
Other outcomes:
Locations:
city: Tokyo
country: Japan
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
citation: Harii K, Kawashima M, Furuyama N, Lei X, Hopfinger R, Lee E. OnabotulinumtoxinA (Botox) in the Treatment of Crow's Feet Lines in Japanese Subjects. Aesthetic Plast Surg. 2017 Oct;41(5):1186-1197. doi: 10.1007/s00266-017-0844-9. Epub 2017 Jul 21.
Clinical trial NCT06912581: Small Bowel Obstruction in Virgin Abdomen
Official title: Management of Virgin Abdomen SBO With a 2-year Follow-up
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Small Bowel Obstruction Adhesion
Keywords: virgin abdomen SBO
Lead sponsor: University of Tartu
Sponsor class: OTHER
Collaborators: name: North Estonia Regional Hospital
First posted: 2025-04-04
Enrollment: 223
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients hospitalised for SBO

Brief summary: A retrospective study conductet at Estonia's two regional hospitals. The data of patients hospitalised for SBO (small bowel obstruction) between 2015-2019 is retrospectively analysed. All other patients are excluded- except for previously unoperated ones (virgin abdomen). Study group analyses whether patients were operated on or was conservative management initiated. It will be studied, if any further medical studies have been done within 2 years of hospitalisation.

Detailed description: Background: The surgical dogma of mandatory operative management of small bowel obstruction (SBO) in patients without prior abdominal operations was re-evaluated by the World Society of Emergency Surgery (WSES) in 2021. A few publications exist on this topic, with a modest number of patients included. The purpose of this study was to analyze the causes and management of small bowel obstruction (SBO) in patients without prior abdominal surgeries.

Methods: Study group retrospectively examined the data of patients hospitalized with SBO from 2015 to 2019. Patients without previous abdominal surgeries-virgin abdomen (VA) were included. Eligible patients' data was evaluated. It was noted whether surgery was performed or conservative management was initiated. In the latter case, information about radiological or endoscopic studies, hospitalizations, or surgeries performed within 2 years after the primary hospitalization was extracted

Eligibility criteria: Inclusion Criteria:

Patients diagnosed with SBO Have not been operated previously

Exclusion Criteria:

Age less than 18 years History of previous operatsions Large bowel obstruction Dynamic ileus

-

Primary outcomes:
measure: SBO resolution at admission
timeFrame: within hospitalisation
Secondary outcomes:
Other outcomes:
Locations:
city: Tartu
country: Estonia
facility: Tartu univeristy clinic
state: Tartumaa
Study officials:
References:
Clinical trial NCT05060081: Comparison of Pilates and Traditional Plank in Recreational Badminton Players.
Official title: Comparison of Pilates and Traditional Plank on Core Muscle Strength, Balance and Agility in Recreational Badminton Players
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sports Physical Therapy
Keywords: Sports Rehabilitation
Pilates
Planks
Strength
Balance
Agility
Badminton
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 28
Sex: ALL
Minimum age (years): 15
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the effects of Pilates exercise and traditional plank exercise training on core muscle strength, balance and agility in recreational badminton players

Detailed description: In modern era, badminton is one of the most famous and played sports worldwide. As compared to other indoor games, badminton is considered to be the finest sports as it occupies a place of pride for both as an individual and team sport. It is a technical and complex sport activity that need massive core strength and whole body strength in strokes, powerful smashes, alertness, well balance and coordination during postural movement in the premises of the court. Notable, to be competitive in badminton, players need to be able to move quickly toward well balanced position that permits them to tackle quickly to hit the shuttlecock.

The purpose of this study is to compare the effects of pilates exercises and traditional plank exercise training on core muscle strength, balance and agility in recreational badminton players.

Eligibility criteria: Inclusion Criteria:

* Players playing badminton for \> 1 year
* Players engaging in badminton ≥ 3 days in a week

Exclusion Criteria:

* History of any injury in past 6 months
* Those players having musculoskeletal, neurological or cardiorespiratory problems
* Those players who have any medical conditions

Primary outcomes:
measure: Star Excursion Balance Test (SEBT)
timeFrame: Six weeks
measure: One Min Sit Up Test
timeFrame: Six weeks
measure: Badcamp Agility Test
timeFrame: Six weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Sports Complex
state: KPK
Study officials:
affiliation: Riphah International University
name: Aadil Omer, Ph.D.*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04811781: Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study
Official title: Epidemiological Features and Clinical Course of SARS-CoV-2 Infection in Cancer Patients Within the Veneto Oncology Network: the ROVID Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Solid Tumor, Adult
Lead sponsor: Istituto Oncologico Veneto IRCCS
Sponsor class: OTHER
First posted: 2021-03-23
Enrollment: 761
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cancer patients with SAR COV-2 infection within the Veneto Oncology Network

Brief summary: The study aims to retrospectively collect epidemiological and clinical data in patients with solid tumors and SARS Covid2 infections belonging to oncology centers within the Veneto Oncology Network

Detailed description: The aim of this study is to create a Veneto Oncology Network with the aim of collecting clinical and epidemiological data of cancer Patients affected by SAR- Covid-2 infection over a period of 1 year. Descriptive statistical approaches will be used to process the data.

The aim is to evaluate the development rate of severe clinical forms of infection in patients with SARS-Cov-2 and the possible association with tumour characteristics and treatment.

In addition, the results of serological tests can be compared with the outcome of the diagnostic swabs and the clinical evolution of the infection in order to obtain more information regarding the significance of specific antibody development.

Eligibility criteria: Inclusion Criteria:

* be 18 Years and older
* cancer patients belonging to Veneto 's Oncological Network
* Patients with SAR COV-2 infection

Exclusion Criteria:

* Patients with no SAR COV2 Infection
* Volunteers
* No Cancer Patients

Primary outcomes:
measure: The rate of SAR-COV2 infection development in association with tumor characteristics.
timeFrame: through study completion, an average of 18 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Padova
country: Italy
facility: istituto Oncologico Veneto -UOSD Melanoma
state: PD
city: Belluno
country: Italy
facility: Aulss1 Dolomiti
city: Padova
country: Italy
facility: Istituto Oncologico Veneto -UOC Oncologia 1
Study officials:
References:
Clinical trial NCT02729181: Assessment of Activities of Daily Living in Adults With Chronic Low Back Pain Using a Nonoperative Treatment Modality
Official title: Assessment of Activities of Daily Living in Adults With Chronic Low Back Pain Using a Nonoperative Treatment Modality: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Low Back Pain
Lead sponsor: Integrity Life Sciences
Sponsor class: OTHER
First posted: 2016-04-06
Enrollment: 116
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pain Management Clinic

Brief summary: The investigators hypothesize that treatment with non-invasive spinal decompression reduces discogenic low back pain (LBP), decreases visual analog pain scale scores, increases activities of daily living and decreases medication use.


Eligibility criteria: Inclusion Criteria:

* at least 18 years of age;
* consented to the physician prescribed protocol;
* presented with discogenic low back pain defined as low back pain for minimum of 12 weeks;
* current CT scan

Exclusion Criteria:

* metastatic cancer;
* previous spinal fusion or placement of stabilization hardware within 6 months;
* instrumentation or artificial discs;
* neurologic motor deficits, bladder, or sexual dysfunction;
* alcohol or drug abuse
* patient's with extremes of height (\< 147 cm or \> 203 cm) and body weight (\> 136 kg).

Primary outcomes:
measure: Lower back pain measured on an 11-point numeric rating scale (VAS) with 0 reflecting no pain at all and 10 the worst imaginable pain.
timeFrame: 12-16 weeks
Secondary outcomes:
measure: Functional capacity, measured by activities of daily living
timeFrame: 12-16 weeks
measure: Proportion of patients using adjuvant analgesic medication
timeFrame: 12-16 weeks
Other outcomes:
Locations:
Study officials:
References: